CN103356663A - Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof - Google Patents
Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof Download PDFInfo
- Publication number
- CN103356663A CN103356663A CN2013102682710A CN201310268271A CN103356663A CN 103356663 A CN103356663 A CN 103356663A CN 2013102682710 A CN2013102682710 A CN 2013102682710A CN 201310268271 A CN201310268271 A CN 201310268271A CN 103356663 A CN103356663 A CN 103356663A
- Authority
- CN
- China
- Prior art keywords
- sulfamonomethoxine
- liquid
- ciprofloxacin
- fosfomycin
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and a preparation method thereof. Every 100mL of the sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use comprises the following components by weight: 5-15g of sulfamonomethoxine sodium, 1-5g of ciprofloxacin, 0.1-0.5g of fosfomycin sodium, 0.5-1.5g of an analgesic, 0.1-0.2g of an antioxidant, 5-20g of a cosolvent, 0.01-0.05g of ethylenediamine tetraacetic acid disodium salt, an appropriate amount of a pH regulator, and the balance of water for injection. The preparation method of the sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection mainly comprises the steps of liquid preparation, filtration, packaging and sterilization. According to the injection, three types of drugs are in reasonable compatibility, and different antibacterial mechanisms of the three drugs are used for inhibiting and killing pathogenic bacteria in various ways, so that the injection has broad-spectrum antibacterial activity and can not generate drug tolerance easily, the dosage is reduced, harms caused by residual antibiotics are lowered, and the safety of livestock and poultry products is ensured favorably.
Description
Technical field
The present invention relates to veterinary drug injection field, relate in particular to sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid and preparation method thereof.
Background technology
Sulfamonomethoxine antibacterial activity in sulfa drugs is the strongest and side effect is minimum, and cost performance is high, uses extensively.Its injection is used sodium-salt form usually, and most of gram positive bacterias and some negative bacterium are had stronger bacteriostasis.Be mainly used in treatment on the veterinary clinic by the microbial baby pig edema of sensitivity, atrophic rhinitis, Actinobacillus property pleuropneumonia, yellow scour of piglet, Hakuri, swine toxoplasmosis, colibacillosis of pigs, Pullorum Disease, avian typhoid, avian colibacillosis, infectious coryza of chicken etc.Sulfamonomethoxine and para-amino benzoic acid competition dihydrofolate synthetase, the synthetic quantity of reduction folic acid, minimizing has the amount of the tetrahydrofolic acid of metabolic activity, has affected the synthetic of nucleotide, thereby has suppressed the growth and breeding of antibacterial.
Ciprofloxacin is third generation Comprecin, it also is enrofloxacin active metabolite in animal body, to gram negative bacilli, particularly enterobacteriaceae lactobacteriaceae such as escherichia coli, Klebsiella pneumonia have the height antibacterial activity, in addition gram-positive staphylococcus, streptococcus pneumoniae etc. also being had good antibacterial action, is powerhouse in the fluoroquinolones used of present veterinary clinic.It belongs to the antibacterial type antimicrobial drug, acts on the A subunit of bacterial cell DNA helicase, suppresses the synthetic of DNA and copies and cause antibacterial dead.Its injection common type is ciprofloxacin lactate, be mainly used in treating poultry colibacillosis, Pullorum Disease, fowl salmonellosis, fowl cholera, chicken chronic respiratory tract disease, yellow scour of piglet, Hakuri, in the bacterial diseasees such as large bowel oedema disease colibacillosis, pig pleuropneumonia and cattle, sheep, rabbit, dog.
Fosfomycin belongs to how Phosphorus broad ectrum antibiotic, and most of gram positive bacterias, negative bacterium are all had killing action.Its molecular structure is simple, and is similar to the phosphoenolpyruvic acid (PEP) at mucopeptide synthetic initial stage of bacteria cell wall, can be combined with the PEP transferring enzyme, suppresses this enzymatic activity, thereby Cell wall synthesis is damaged and causes antibacterial dead.Fosfomycin is combined with plasma protein hardly, no antigen, drug resistance are low, and not yet finds and other antibacterials crossing drug resistant so far, and having possessed in addition distributes in antiinflammatory action, the body extensively, does not degrade and the advantage such as drug safety height.Its injection is used sodium-salt form usually.At present on the veterinary clinic with the oral way administration, be mainly used in treating the mixed infection that avian colibacillosis and Salmonella, staphylococcus, fowl cholera etc. cause, and mycoplasma pneumoniae of swine, pig pleuropneumonia, pig streptococcicosis, yellow scour of piglet, Hakuri etc.
In present treatment, because single variety Injection for animals curative effect is single, often can not effectively control mixed infection or secondary infection, in order to reach therapeutic purposes, have to for a long time, repeatedly, escalated dose uses antibiotic, not only increased production cost, and produced untoward reaction and the residual harm of medicine, cause bacterial drug resistance to increase, bring very large difficulty for the sustainable prevention and control of livestock and poultry pestilence.Detected the dihydrofolate synthetase gene that sulphonamides is had resistance in bibliographical information part pig source Salmonella and the escherichia coli.The quinolones life-time service causes the gram-positive staphylococcus aureus of part and staphylococcus epidermidis to change fastbacteria into by sensitive organism, for the drug resistance of ciprofloxacin up to more than 60%.Some conditioned pathogens such as Pseudomonas aeruginosa, escherichia coli, Klebsiella pneumonia, enterobacteria etc. also present in various degree drug resistance to quinolones, and are year by year ascendant trend.
Some Antibiotic combination uses, can enlarge antimicrobial spectrum, and its antibacterial activity addition is coordinated, utilize different Antibacterial Mechanisms from the Growth and reproduction of each approach blocking-up antibacterial, with preventing and treating a series of epidemic diseases that mixed infection or secondary infection cause than low dosage, and be difficult for causing bacterial drug resistance or cross resistance, also can play good inhibition or killing effect to existing fastbacteria.In vitro study confirms, fosfomycin and beta-lactam, aminoglycoside, quinolones, sulfa drugs coupling, Pseudomonas aeruginosa, escherichia coli, acinetobacter calcoaceticus, methicillin-resistant Staphylococcus etc. are presented well collaborative and summation action, make antibacterial activity all each prescription with increasing several times to tens times.Quinolones and penicillins, aminoglycoside, Tetracyclines, sulfa drugs coupling also have synergistic function.CN1843328A discloses compound enrofloxacin-sulfamonomethoxine daimeton injection and preparation method thereof, its therapeutic effect uses more separately enrofloxacin injection or sulfamonomethoxine daimeton injection to be greatly improved, but it is still not obvious to the microbial mixed infections such as escherichia coli, Salmonella, staphylococcus, streptococcus, Bacillus proteus, shigella, Klebsiella pneumonia and secondary infection effect.
Summary of the invention
The present invention is directed to the pathogenic bacterium of using antibiotic to cause separately in the prior art and easily produce drug resistance, the deficiency that dosage is large, antibiotic remains is serious provides a kind of has a broad antifungal spectrum, few, the bland sulfamonomethoxine-ciprofloxacin for animals of use amount-fosfomycin joint injection liquid and preparation method thereof.
In order to solve the problems of the technologies described above, the present invention is solved by following technical proposals.
Sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid is characterized in that, every 100mL sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid comprises following component:
In sulfamonomethoxine-ciprofloxacin for animals of the present invention-fosfomycin joint injection liquid, adopt broad spectrum antibiotic sulfamonomethoxine, ciprofloxacin and the fosfomycin of different antimicrobial spectrums and Antibacterial Mechanism, the three unites use, suppress even kill Gram-positive and gram negative bacteria from different approach, can be used for treating serious general mixed infection and secondary infection; In addition, because addition and the synergy of antibacterial action, drug effect can strengthen, thereby reduces antibiotic use amount, reduces antibiotic remains harm, is conducive to guarantee the animal products quality safety.
As preferably, analgesic is one or both in benzyl alcohol, procaine hydrochloride or the diclofenac sodium.Fosfomycin sodium intramuscular injection local pain is more violent, and the adding of benzyl alcohol or procaine hydrochloride can play local anaesthetic effect, alleviates intramuscular injection pain.But diclofenac sodium anti-inflammatory analgesic.In addition, benzyl alcohol also can be sterilized anticorrosion, the prolong drug shelf-life.
As preferably, antioxidant is one or both in sodium thiosulfate, sodium sulfite or the ascorbic acid.Have fragrant primary amino radical in the sulfamonomethoxine molecular structure, the possibility of oxidation stain is arranged, add sodium thiosulfate or sodium sulfite or ascorbic acid as antioxidant, can prevent effectively that sulfamonomethoxine lost efficacy because of oxidation stain.Sodium thiosulfate or sodium sulfite are applicable to the meta-alkalescence injection, and ascorbic acid can be used for the alkalescence injection.
As preferably, cosolvent is one or both in PEG400, propylene glycol or the polyvinylpyrrolidone.
As preferably, pH adjusting agent is ethanolamine and lactic acid, regulates pH value between 9.5-10.5.Select ethanolamine and lactic acid as pH adjusting agent, during actual preparation, pH exceeds described scope, regulates with lactic acid, and pH is lower than described scope, regulates with ethanolamine; Select pH value between 9.5-10.5, can satisfy the adaptability requirement of body, reduce medicine irritation, can keep again the stability of injection.
The preparation method of sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid is comprised of following step successively,
(1) water for injection with 10-20mL dissolves the sulfamonomethoxine sodium of 5-15g and the fosfomycin sodium of 0.1-0.5g successively, makes A liquid;
(2) behind the cosolvent with the water for injection stirring and dissolving 5-20g of 10-20mL, add the ciprofloxacin of 1-5g, fully stir, add again the ethanolamine of 4-10g, fully after the dissolving, make B liquid;
(3) A liquid is joined in the B liquid, be stirred well to clear, make C liquid;
(4) add the analgesic of 0.5-1.5g, the antioxidant of 0.1-0.2g, the disodiumedetate of 0.01-0.05g in the C liquid, be stirred well to dissolving, make D liquid;
(5) add pH adjusting agent in the D liquid, adjust pH is 9.5-10.5, adds water for injection again and is settled to 100mL, makes E liquid;
(6) embedding after E liquid filters through 0.15MPa, 115 ℃ of sterilization 15min, obtains finished product.
The invention has the beneficial effects as follows:
1. though principal agent sulfamonomethoxine, ciprofloxacin and fosfomycin are broad spectrum antibiotic, Antibacterial Mechanism is different, and antimicrobial spectrum and action effect there are differences, and when using separately, antibacterial easily produces drug resistance to sulfamonomethoxine and ciprofloxacin.The three unites use, can even kill Gram-positive and gram negative bacteria from different approach inhibition, has enlarged antimicrobial spectrum on the one hand, can be used for treating serious general mixed infection and secondary infection, even can see through blood brain barrier, the treatment brain infection; Antibacterial action presents addition and synergy on the other hand, and drug effect can strengthen several times and even decades of times, uses can reach therapeutic effect than low dosage, and is difficult for causing bacterial drug resistance.Popularization of the present invention is conducive to the sustainable prevention and control of livestock and poultry pestilence, promotes plant to increase economic benefit, ensures the quality safety of animal products from the source.
2. but the concurrent inflammation of fosfomycin sodium auxiliary treatment antibacterial, but the intramuscular injection local pain is more violent.Add analgesic among the present invention, can play local anaesthetic effect, alleviate intramuscular injection pain.Benzyl alcohol also can be sterilized anticorrosion, the prolong drug shelf-life.Add antioxidant, prevented the oxidation stain of fragrant primary amino radical in the sulfamonomethoxine molecular structure.Injection selects pH value between 9.5-10.5, can satisfy the adaptability requirement of body, reduces medicine irritation, can keep again the stability of injection.The mode administration of intramuscular injection is adopted in suggestion, veterinary clinic is used more convenient.
3. sulfamonomethoxine sodium and fosfomycin sodium are alkalescence in aqueous solution, ciprofloxacin can be dissolved in alkaline solution, regulate the pH value of injection by ethanolamine and lactic acid, can realize the reasonable compatibility of these three kinds of medicines, avoid the clinically improper side effect that causes of sequential infusion compatibility.In addition, add the dispersion that cosolvent is conducive to medicine, improved stability and the frost resistance of injection.
4. existing sulfamonomethoxine sodium, ciprofloxacin and fosfomycin sodium injection stage product are united use in the market, have saved production cost, have improved added value of product; And the injection preparation of development is simple, is suitable for industrialized large-scale production.
The specific embodiment
Below in conjunction with embodiment the present invention is described in further detail.
Embodiment 1
Sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid, this injection of every 100mL comprises following component:
Wherein, regulating pH value is 9.7.
This sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid adopts the following steps preparation:
(1) water for injection with 20mL dissolves the sulfamonomethoxine sodium of 10g and the fosfomycin sodium of 0.2g successively, makes A liquid;
(2) behind the PEG400 with the water for injection stirring and dissolving 10g of 20mL, add the ciprofloxacin of 2g, fully stir, add again an amount of ethanolamine, fully after the dissolving, make B liquid;
(3) A liquid is joined in the B liquid, be stirred well to clear, make C liquid;
(4) add the benzyl alcohol of 1g, the sodium thiosulfate of 0.1g, the disodiumedetate of 0.01g in the C liquid, be stirred well to dissolving, make D liquid;
(5) add pH adjusting agent in the D liquid, adjust pH to 9.7, adding water for injection to cumulative volume is 100mL again, makes E liquid;
(6) E liquid obtains filtrate behind organic membrane filtration of 0.45 μ m, is sub-packed in the cillin bottle of 10mL, namely gets above-mentioned injection finished product behind 115 ℃, 0.15MPa sterilization 15min.
Embodiment 2
Sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid, this injection of every 100mL comprises following component:
Wherein, regulating pH value is 9.8.
The step of preparation method is identical with embodiment 1.
Embodiment 3
Sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid, this injection of every 100mL comprises following component:
Wherein, regulating pH value is 10.2.
The step of preparation method is identical with embodiment 1.
Embodiment 4
Sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid, this injection of every 100mL comprises following component:
Wherein, regulating pH value is 9.5.
The step of preparation method is identical with embodiment 1.
Embodiment 5
Sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid, this injection of every 100mL comprises following component:
Wherein, regulating pH value is 10.5.
The step of preparation method is identical with embodiment 1.
Embodiment 6
Sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid, this injection of every 100mL comprises following component:
Wherein, regulating pH value is 10.0.
The step of preparation method is identical with embodiment 1.
Embodiment 7
Clinical trial:
1. laboratory animal
Certain scale pig farm, ill piglet, body weight is about 20kg.Cardinal symptom is: anorexia, and fever, diarrhoea is arranged yellow medicated porridge sample feces, stench.Be diagnosed as the mixed infection that various pathogens causes.
2. experimental technique
Test pig is divided into 4 groups at random.
The A group does not give Drug therapy for the blank group.
The B group is treated with sulfamonomethoxine sodium injection for animals.Usage: the musculi colli injection, every 1kg body weight 0.2mL 2 times on the one, is used in conjunction 3.
The C group is treated with ciprofloxacin lactate injection for animals.Usage: the musculi colli injection, every 1kg body weight 0.2mL 2 times on the one, is used in conjunction 3.
The D group is treated with sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid.Usage: the musculi colli injection, every 1kg body weight 0.2mL 1 time on the one, is used in conjunction 3.
3. result and discussion
1 all viewing test pig health situations of change after the treatment, statistical result sees Table 1.Inefficiency be symptom without obviously change, sb.'s illness took a turn for the worse or dead test pig ratio.Effective percentage is the test pig ratio that symptom is better than treating front effect.Cure rate is that body temperature, appetite, feces recover normal test pig ratio.Obviously, three kinds of injection all have certain therapeutical effect to this disease.Therapeutic effect of the present invention significantly is better than other two kinds of folk prescription injection, can effectively improve the state of an illness, and cure rate reaches 90%.
The therapeutic effect contrast of table 1 the present invention and other injection
In a word, the above only is preferred embodiment of the present invention, and all equalizations of doing according to the present patent application claim change and modify, and all should belong to the covering scope of patent of the present invention.
Claims (6)
1. sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid, it is characterized in that: every 100mL sulfamonomethoxine-ciprofloxacin for animals-fosfomycin joint injection liquid comprises following component:
2. sulfamonomethoxine-ciprofloxacin for animals according to claim 1-fosfomycin joint injection liquid, it is characterized in that: analgesic is one or both in benzyl alcohol, procaine hydrochloride or the diclofenac sodium.
3. sulfamonomethoxine-ciprofloxacin for animals according to claim 1-fosfomycin joint injection liquid, it is characterized in that: antioxidant is one or both in sodium thiosulfate, sodium sulfite or the ascorbic acid.
4. sulfamonomethoxine-ciprofloxacin for animals according to claim 1-fosfomycin joint injection liquid, it is characterized in that: cosolvent is one or both in PEG400, propylene glycol or the polyvinylpyrrolidone.
5. sulfamonomethoxine-ciprofloxacin for animals according to claim 1-fosfomycin joint injection liquid, it is characterized in that: pH adjusting agent is ethanolamine and lactic acid.
6. the preparation method of sulfamonomethoxine-ciprofloxacin for animals according to claim 1-fosfomycin joint injection liquid is characterized in that: formed by following step successively,
(1) water for injection with 10-20mL dissolves the sulfamonomethoxine sodium of 5-15g and the fosfomycin sodium of 0.1-0.5g successively, makes A liquid;
(2) behind the cosolvent with the water for injection stirring and dissolving 5-20g of 10-20mL, add the ciprofloxacin of 1-5g, fully stir, add again the ethanolamine of 4-10g, fully after the dissolving, make B liquid;
(3) A liquid is joined in the B liquid, be stirred well to clear, make C liquid;
(4) add the analgesic of 0.5-1.5g, the antioxidant of 0.1-0.2g, the disodiumedetate of 0.01-0.05g in the C liquid, be stirred well to dissolving, make D liquid;
(5) add pH adjusting agent in the D liquid, adjust pH is 9.5-10.5, and adding water for injection to cumulative volume is 100mL again, makes E liquid;
(6) embedding after E liquid filters through 0.15MPa, 115 ℃ of sterilization 15min, obtains finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102682710A CN103356663A (en) | 2013-06-28 | 2013-06-28 | Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102682710A CN103356663A (en) | 2013-06-28 | 2013-06-28 | Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356663A true CN103356663A (en) | 2013-10-23 |
Family
ID=49359479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102682710A Pending CN103356663A (en) | 2013-06-28 | 2013-06-28 | Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356663A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108883062A (en) * | 2016-03-16 | 2018-11-23 | 阿珀斯托洛斯·吉奥格博洛斯 | The phosphonomycin preparation of administration for parenteral route |
| CN110870849A (en) * | 2019-12-20 | 2020-03-10 | 四川志邦生物科技有限公司 | Sulfamonomethoxine sodium injection and preparation method and preparation system thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843328A (en) * | 2006-05-10 | 2006-10-11 | 天津生机集团有限公司 | Enrofloxacin and sulfamonomethoxine injection, and its preparation method |
| CN101574355A (en) * | 2009-06-01 | 2009-11-11 | 河南新正好生物工程有限公司 | Compound antibacterial injection for livestock and preparation method thereof |
| CN101816663A (en) * | 2009-02-26 | 2010-09-01 | 河南惠通天下动物药业有限公司 | Medicinal composition and injecta for curing avian toxoplasmosis, and preparation method thereof |
| CN101991587A (en) * | 2010-12-08 | 2011-03-30 | 纽素乐必佳（天津）药业集团有限公司 | Compound sulfadiazine injection and preparation method thereof |
| CN103006674A (en) * | 2012-12-14 | 2013-04-03 | 江苏恒丰强生物技术有限公司 | Compound sulfamonomethoxine sodium solution and preparation method thereof |
-
2013
- 2013-06-28 CN CN2013102682710A patent/CN103356663A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843328A (en) * | 2006-05-10 | 2006-10-11 | 天津生机集团有限公司 | Enrofloxacin and sulfamonomethoxine injection, and its preparation method |
| CN101816663A (en) * | 2009-02-26 | 2010-09-01 | 河南惠通天下动物药业有限公司 | Medicinal composition and injecta for curing avian toxoplasmosis, and preparation method thereof |
| CN101574355A (en) * | 2009-06-01 | 2009-11-11 | 河南新正好生物工程有限公司 | Compound antibacterial injection for livestock and preparation method thereof |
| CN101991587A (en) * | 2010-12-08 | 2011-03-30 | 纽素乐必佳（天津）药业集团有限公司 | Compound sulfadiazine injection and preparation method thereof |
| CN103006674A (en) * | 2012-12-14 | 2013-04-03 | 江苏恒丰强生物技术有限公司 | Compound sulfamonomethoxine sodium solution and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 周旭美 等: "磷霉素与环丙沙星联用的体外抗生素后效应研究", 《贵州医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108883062A (en) * | 2016-03-16 | 2018-11-23 | 阿珀斯托洛斯·吉奥格博洛斯 | The phosphonomycin preparation of administration for parenteral route |
| CN110870849A (en) * | 2019-12-20 | 2020-03-10 | 四川志邦生物科技有限公司 | Sulfamonomethoxine sodium injection and preparation method and preparation system thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9012429B2 (en) | Methods and compositions for the prevention of and treatment of infections utilizing chitosan-derivative compounds | |
| JP5808860B2 (en) | Pharmaceutical composition comprising sulbactam and beta-lactamase inhibitor | |
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| JP2017125031A (en) | Methods of treatment using 3-bromopyruvate and other selective inhibitors of atp production | |
| CN101822688B (en) | Compound tylosin injection for animals and preparation method thereof | |
| CN101829124B (en) | Veterinary compound sulfadiazine sodium injection and preparation method thereof | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN103356663A (en) | Sulfamonomethoxine-ciprofloxacin-fosfomycin combined injection for veterinary use and preparation method thereof | |
| CN101829129B (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| CN103721240B (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN102793713A (en) | Lincomycin hydrochloride-spectinomycin sulfate injection and preparation method thereof | |
| CN101011402A (en) | Compound sulfadimidine sodium injection and its preparation method | |
| CN101199520A (en) | Beta-Lacetam anti-biotic compound dose for animal containing benemid | |
| CN102813909A (en) | Compound doxycycline hydrochloride composition for preventing and treating colibacillosis and chronic respiratory disease of poultry as well as preparation method thereof | |
| CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
| CN101849947A (en) | Composition of cefazedone sodium and tazobactam sodium and ratio of cefazedone sodium to tazobactam sodium | |
| CN1985827B (en) | Compound ciprofloxacin injection for animal and its preparing process | |
| CN117679362B (en) | Veterinary valnemulin solution and preparation method and application thereof | |
| RU2691139C1 (en) | Method of treating diseased calves with salmonellosis | |
| CN101015560A (en) | Compound suladime sulfadiazine sodium injection and its preparation | |
| RU2710712C1 (en) | Preparation for prevention of mass gastrointestinal diseases of young cattle from birth to one month | |
| CN101505740A (en) | Improved method of treatment of bacterial infections | |
| CN1098076C (en) | Oral linmerjing as one kind of powerful anti-bacterial medicine | |
| CN102743395B (en) | Compound ofloxacin injecta and preparation method thereof | |
| CN112618555A (en) | Application of aspirin and ciprofloxacin in preparation of medicine for treating urinary tract infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131023 |